Skip to content
10-K

Annual Report

Solid Biosciences Inc. SLDB

0001193125-26-115928

← back to feed
Filed
Mar 19, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 16, 2026 98.39M sh
Shares Diluted FY 2025 · Dec 31, 2025 87.5M sh
Shares Diluted FY 2025 · Dec 31, 2024 40.82M sh
Capex FY 2025 · Dec 31, 2025 $1.15M
Capex FY 2025 · Dec 31, 2024 $654K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$156.29M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$100.01M
Cash And Equivalents FY 2025 · Dec 31, 2025 $59.9M
Cash And Equivalents FY 2025 · Dec 31, 2024 $80.24M
Stockholders Equity FY 2025 · Dec 31, 2025 $180.01M
Stockholders Equity FY 2025 · Dec 31, 2024 $137.25M
Stockholders Equity FY 2025 · Dec 31, 2023 $126.48M
Current Liabilities FY 2025 · Dec 31, 2025 $33.47M
Current Liabilities FY 2025 · Dec 31, 2024 $30.26M
Total Liabilities FY 2025 · Dec 31, 2025 $52.53M
Total Liabilities FY 2025 · Dec 31, 2024 $51.42M
Current Assets FY 2025 · Dec 31, 2025 $205.46M
Current Assets FY 2025 · Dec 31, 2024 $157.3M
Total Assets FY 2025 · Dec 31, 2025 $232.54M
Total Assets FY 2025 · Dec 31, 2024 $188.66M
Eps Diluted FY 2025 · Dec 31, 2025 −$1.99
Eps Diluted FY 2025 · Dec 31, 2024 −$3.06
Eps Basic FY 2025 · Dec 31, 2025 −$1.99
Eps Basic FY 2025 · Dec 31, 2024 −$3.06
Sga Expense FY 2025 · Dec 31, 2025 $38.88M
Sga Expense FY 2025 · Dec 31, 2024 $33.3M
Rd Expense FY 2025 · Dec 31, 2025 $140.33M
Rd Expense FY 2025 · Dec 31, 2024 $96.43M
Operating Income FY 2025 · Dec 31, 2025 −$179.21M
Operating Income FY 2025 · Dec 31, 2024 −$129.73M